Subsequent molecular biology experiments demonstrated that brusatol ameliorates psoriasis-associated dyslipidemia by modulating the AMPK-mediated SREBP-1c/FASN and PPARα/CPT1A signaling pathways. The gene discussed is FASN; the disease is psoriasis.